The Latest Breaking News from Amit Hasija

Milestone Pharmaceuticals Q1 Earnings Call Highlights

Milestone Pharmaceuticals (NASDAQ:MIST) said its first quarter of 2026 marked the beginning of commercial sales for CARDEMYST, its newly approved treatment for acute episodes of paroxysmal supraventricular tachycardia, or PSVT, while the company also moved ahead with a Phase 3 program in atrial fibr

MarketBeat · May 13